Am J Perinatol 2014; 31(09): 735-740
DOI: 10.1055/s-0033-1359720
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

The Effects of Intermittent Pneumatic Compression during Cesarean Delivery on Fibrinolysis

Keisha L. B. Reddick
1   Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina
,
Michael P. Smrtka
1   Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina
,
Chad A. Grotegut
1   Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina
,
Andra H. James
2   Department of Obstetrics and Gynecology, University of Virginia, Charlottesville, Virginia
,
Leo R. Brancazio
1   Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina
,
Geeta K. Swamy
1   Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina
› Author Affiliations
Further Information

Publication History

22 August 2013

04 September 2013

Publication Date:
11 December 2013 (online)

Abstract

Objective Pregnancy is associated with increased risk for thromboembolic events. Intermittent pneumatic compression (IPC) devices are the method of thromboprophylaxis in a nonpregnant population. The aim of this study was to examine the effects of IPC on markers of fibrinolysis during cesarean delivery.

Study Design We conducted a randomized controlled trial from April 2009 to March 2010 of women undergoing scheduled elective cesarean delivery. Forty-nine women were randomized to IPCs or usual care. All participants had three blood samples obtained: (1) baseline, (2) 1 hour after randomization, and (3) 30 minutes after cesarean delivery. Tissue-type plasminogen activator (tPA), urokinase-type plasminogen activator (uPA), thrombin-antithrombin complex (TAT), plasminogen activator inhibitor-1 (PAI-1), and plasminogen activator inhibitor-2 (PAI-2) levels were analyzed in each sample using an enzyme-linked immunosorbent assay. Statistical analysis was performed using repeated measures two-way analysis of variance with α = 0.05.

Results There was a time-dependent change in tPA, uPA, and PAI-1 levels following delivery but no difference in TAT and PAI-2 levels with time. There were no differences between women randomized to IPCs or usual care.

Conclusion Markers of fibrinolysis were not significantly altered by IPCs in this study of low-risk pregnant women. Further research regarding the mechanism and efficacy of IPCs in pregnant women is warranted.

 
  • References

  • 1 James AH. Prevention and management of venous thromboembolism in pregnancy. Am J Med 2007; 120 (10) (Suppl. 02) S26-S34
  • 2 Clark SL, Belfort MA, Dildy GA, Herbst MA, Meyers JA, Hankins GD. Maternal death in the 21st century: causes, prevention, and relationship to cesarean delivery. Am J Obstet Gynecol 2008; 199 (1) e1-e5 , discussion 91–92, e7–e11
  • 3 James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol 2006; 194 (5) 1311-1315
  • 4 Sia WW, Powrie RO, Cooper AB , et al. The incidence of deep vein thrombosis in women undergoing cesarean delivery. Thromb Res 2009; 123 (3) 550-555
  • 5 Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton III LJ. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005; 143 (10) 697-706
  • 6 Joint Commission on Accreditation of Healthcare Organizations, USA. Preventing maternal death. Sentinel Event Alert 2010; (44) 1-4
  • 7 Burrows RF, Gan ET, Gallus AS, Wallace EM, Burrows EA. A randomised double-blind placebo controlled trial of low molecular weight heparin as prophylaxis in preventing venous thrombolic events after caesarean section: a pilot study. BJOG 2001; 108 (8) 835-839
  • 8 Quiñones JN, James DN, Stamilio DM, Cleary KL, Macones GA. Thromboprophylaxis after cesarean delivery: a decision analysis. Obstet Gynecol 2005; 106 (4) 733-740
  • 9 Ferres MA, Olivarez SA, Trinh V, Davidson C, Sangi-Haghpeykar H, Aagaard-Tillery KM. Rate of wound complications with enoxaparin use among women at high risk for postpartum thrombosis. Obstet Gynecol 2011; 117 (1) 119-124
  • 10 Snijder CA, Cornette JM, Hop WCJ, Kruip MJ, Duvekot JJ. Thrombophylaxis and bleeding complications after cesarean section. Acta Obstet Gynecol Scand 2012; 91 (5) 560-565
  • 11 Clarke-Pearson DL, Creasman WT, Coleman RE, Synan IS, Hinshaw WM. Perioperative external pneumatic calf compression as thromboembolism prophylaxis in gynecologic oncology: report of a randomized controlled trial. Gynecol Oncol 1984; 18 (2) 226-232
  • 12 Comerota AJ, Chouhan V, Harada RN , et al. The fibrinolytic effects of intermittent pneumatic compression: mechanism of enhanced fibrinolysis. Ann Surg 1997; 226 (3) 306-313 , discussion 313–314
  • 13 Tarnay TJ, Rohr PR, Davidson AG, Stevenson MM, Byars EF, Hopkins GR. Pneumatic calf compression, fibrinolysis, and the prevention of deep venous thrombosis. Surgery 1980; 88 (4) 489-496
  • 14 Knight MT, Dawson R. Effect of intermittent compression of the arms on deep venous thrombosis in the legs. Lancet 1976; 2 (7998) 1265-1268
  • 15 Salzman EW, McManama GP, Shapiro AH , et al. Effect of optimization of hemodynamics on fibrinolytic activity and antithrombotic efficacy of external pneumatic calf compression. Ann Surg 1987; 206 (5) 636-641
  • 16 Cahan MA, Hanna DJ, Wiley LA, Cox DK, Killewich LA. External pneumatic compression and fibrinolysis in abdominal surgery. J Vasc Surg 2000; 32 (3) 537-543
  • 17 Gallus AS, Hirsh J. Prevention of venous thromboembolism. Semin Thromb Hemost 1976; 2 (4) 232-290
  • 18 Casele H, Grobman WA. Cost-effectiveness of thromboprophylaxis with intermittent pneumatic compression at cesarean delivery. Obstet Gynecol 2006; 108 (3, Pt 1) 535-540
  • 19 Marik PE, Plante LA. Venous thromboembolic disease and pregnancy. N Engl J Med 2008; 359 (19) 2025-2033
  • 20 Ellison J, Thomson AJ, Conkie JA, McCall F, Walker D, Greer A. Thromboprophylaxis following caesarean section—a comparison of the antithrombotic properties of three low molecular weight heparins—dalteparin, enoxaparin and tinzaparin. Thromb Haemost 2001; 86 (6) 1374-1378
  • 21 Fox NS, Laughon SK, Bender SD, Saltzman DH, Rebarber A. Anti-factor Xa plasma levels in pregnant women receiving low molecular weight heparin thromboprophylaxis. Obstet Gynecol 2008; 112 (4) 884-889
  • 22 Brancazio LR, Roperti KA, Stierer R, Laifer SA. Pharmacokinetics and pharmacodynamics of subcutaneous heparin during the early third trimester of pregnancy. Am J Obstet Gynecol 1995; 173 (4) 1240-1245
  • 23 Stirrup CA, Lucas DN, Cox ML , et al. Maternal anti-factor Xa activity following subcutaneous unfractionated heparin after Caesarean section. Anaesthesia 2001; 56 (9) 855-858
  • 24 Horlocker TT, Wedel DJ, Rowlingson JC , et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). Reg Anesth Pain Med 2010; 35 (1) 64-101
  • 25 Woodfield DG, Cole SK, Allan AG, Cash JD. Systemic fibrinolysis during and following elective caesarean section and gynaecological operations. J Obstet Gynaecol Br Commonw 1972; 79 (6) 538-543
  • 26 Choi JW, Pai SH. Tissue plasminogen activator levels change with plasma fibrinogen concentrations during pregnancy. Ann Hematol 2002; 81 (11) 611-615
  • 27 Brenner B. Haemostatic changes in pregnancy. Thromb Res 2004; 114 (5-6) 409-414
  • 28 Kruithof EK, Tran-Thang C, Gudinchet A , et al. Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood 1987; 69 (2) 460-466
  • 29 Jacobsen AF, Drolsum A, Klow NE, Dahl GF, Qvigstad E, Sandset PM. Deep vein thrombosis after elective cesarean section. Thromb Res 2004; 113 (5) 283-288